Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company.

It focuses on developing
pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. The
company is developing Zygel, a transdermal cannabidiol gel, which is in Phase II clinical trial for treating children and
adolescent patients with developmental and epileptic encephalopathies; is in Phase II clinical trial for treating children
and adolescent patients with autism spectrum disorder; is in Phase II clinical trial for treating pediatric behavioral and
emotional symptoms of 22q11.2 deletion syndrome; and to treat children and adolescent patients with fragile X
syndrome. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc.
in August 2014. Zynerba Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Devon, Pennsylvania.

Zynerba Pharmaceuticals (ZYNE) closed at $4.15 in the latest trading session, marking a +1.47% move from the prior
day. This change lagged the S&P 500's 1.95% gain on the day. Elsewhere, the Dow gained 1.85%, while the tech-heavy
Nasdaq added 1.55%.

Prior to today's trading, shares of the specialty pharmaceutical company had lost 9.31% over the past month. This has
lagged the Medical sector's loss of 6.76% and the S&P 500's loss of 2.45% in that time.

Wall Street will be looking for positivity from ZYNE as it approaches its next earnings report date. The company is
expected to report EPS of -$0.38, up 17.39% from the prior-year quarter.

It is also important to note the recent changes to analyst estimates for ZYNE. These recent revisions tend to reflect the
evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of
optimism about the company's business outlook.

Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We
developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and
delivers a clear, actionable rating model.

Previous Close 4.0900

Open 4.1000
Bid
4.1600 x 1100
Ask
4.1900 x 1000
Day's Range
3.5500 - 4.1900
52 Week Range
2.5500 - 9.0000
Volume 2,967,290
Avg. Volume 5,400,281

Market Cap 122.173M

Beta (5Y Monthly) 2.82

PE Ratio (TTM) N/A

EPS (TTM) -2.0570

Earnings Date Nov 08, 2020

Forward Dividend & Yield N/A

Ex-Dividend Date (N/A)

1y Target Est
7.25